0% found this document useful (0 votes)
6 views2 pages

Anotation 3

The NSF-Piedmont Triad RegenMed Engine Test Bed has partnered with SABEU to enhance product development in regenerative medicine. This collaboration aims to leverage SABEU's extensive manufacturing expertise to streamline processes and improve efficiency for Test Bed participants. The initiative is part of a broader effort to accelerate the translation of regenerative medicine research into commercial applications, ultimately benefiting global health outcomes.

Uploaded by

asona
Copyright
© All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
0% found this document useful (0 votes)
6 views2 pages

Anotation 3

The NSF-Piedmont Triad RegenMed Engine Test Bed has partnered with SABEU to enhance product development in regenerative medicine. This collaboration aims to leverage SABEU's extensive manufacturing expertise to streamline processes and improve efficiency for Test Bed participants. The initiative is part of a broader effort to accelerate the translation of regenerative medicine research into commercial applications, ultimately benefiting global health outcomes.

Uploaded by

asona
Copyright
© All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd

2024 AUG 18 (VerticalNews) -- By a News Reporter-Staff News Editor at VerticalNews

Health -- Winston-Salem, North Carolina - - The NSF-Piedmont Triad RegenMed


Engine (PTRME) Test Bed, located in Innovation Quarter, introduces strategic
partnership with SABEU, a leader in injection molding and mold making since 1958. The
alliance brings over 30 years of expertise in manufacturing for life sciences to Test Bed
participants - a collaboration aiming to leverage the combined strengths and expertise
of both organizations to drive innovation and excellence in product development for
regenerative medicine. The Test Bed is an initiative by the RegenMed Development
Organization (ReMDO), a non-profit dedicated to accelerating regenerative medicine
therapies.

SABEU's long-standing experience, certified by DIN EN ISO 9001 and DIN EN ISO
13485 standards, positions it as an ideal partner for regenerative medicine. The
company's ability to provide comprehensive solutions from a single source sets it apart
from other suppliers. The SABEU cellQART® is a high quality cell culture insert for
cultivation, with semipermeable membranes and a split chamber compartment that
helps to keep the inserts in place. These state-of-the-art inserts benefit cell growth for in
vivo testing, allowing free access to apply growth materials and substances from all
sides. For Test Bed members, this means well-built equipment to continue their
research, saving time and financial resources to accelerate their products to market.

With capabilities in clean room manufacturing and company agility, SABEU is uniquely
positioned to meet the diverse needs of biomanufacturing companies. The Test Bed will
enable SABEU to gain inside knowledge on those needs and continue to build a library
of supplies. By pooling resources, SABEU and the NSF-PTRME Test Bed will
streamline the manufacturing and testing of products like TRAKETCH® ion-track
membrane and cellQART®, resulting in efficient cost structures and simplified supply
chain management. In 2017, SABEU entered the innovative R&D space, developing an
onsite tool shop, ISO Class 8 clean rooms, QA, logistics and management in Northeim,
Germany.

"The cellQART inserts, TRAKETCH® ion-track membranes and other SABEU products
are a perfect fit for Test Bed members because of their high quality and flexibility to be
used in a variety of testing scenrios," explained Joshua Hunsberger, CTO for ReMDO.
"The key to moving new therapies and materials to market to help real patients is
efficiency, and we are confident in SABEU's legacy of over 30 years in manufacturing."

The introduction of SABEU into the Test Bed signifies continued steps to build and
support the ecosystem. In this ecosystem, research in biomedical innovation works to
pioneer new standards in biotechnology, facilitating breakthroughs that enhance global
health outcomes.
About SABEU GmbH & Co. KG: SABEU is offering expertise in injection molding and
mold making since 1958 as well as over 30 years in the processing and manufacturing
of membranes for Life Sciences, Medical, Packaging and further Industries.

About ReMDO: The RegenMed Development Organization (ReMDO) is a 501©3


non-profit with a mission to help deliver on the promise of regenerative medicine by
advancing research to de-risk technologies, promoting progress of biomanufacturing
scale-up and automation to make technologies more affordable, and speeding up the
translation to clinical practice. For more information, visit [Link]

For inquiries regarding the RegeneratOR Test Bed and partnership opportunities,
please contact info@[Link].

About the NSF-PTRME: The NSF-PTRME is an initiative to build a regional innovation


ecosystem to accelerate the translation of regenerative medicine use-inspired
research to commercialization, thus stimulating economic growth, workforce
development, and job creation. The PTRME partnership consists of members of the
RegenMed Hub, ReMDO, members of the Regenerative Manufacturing Innovation
Consortium (RegMIC), and includes more than 80 regional stakeholders in academia,
industry, government, and not-for profit entities. The PTRME core team consists of
organizations in the industry with Axiom Space and ReMDO paired with academic
institutions such as North Carolina Agricultural and Technical State University (NC
A&T), Winston Salem State University (WSSU), and Forsyth Technical Community
College, supported by multiple businesses, governmental entities, and not-for-profit
agencies.

The RegenMed Test Bed in North Carolina is working with SABEU, a company that’s been
doing lab and medical stuff forever. They’re helping researchers get better tools and faster ways
to make new regenerative medicine treatments. It could get therapies to patients quicker, but
there are still problems, like keeping costs low, dealing with different company needs, and
figuring out how to scale everything.

You might also like